MA41123A - Polythérapie pour le traitement du cancer - Google Patents

Polythérapie pour le traitement du cancer

Info

Publication number
MA41123A
MA41123A MA041123A MA41123A MA41123A MA 41123 A MA41123 A MA 41123A MA 041123 A MA041123 A MA 041123A MA 41123 A MA41123 A MA 41123A MA 41123 A MA41123 A MA 41123A
Authority
MA
Morocco
Prior art keywords
polytherapy
cancer treatment
cancer
treatment
Prior art date
Application number
MA041123A
Other languages
English (en)
Inventor
Austin Gurney
Timothy Charles Hoey
Wan-Ching Yen
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of MA41123A publication Critical patent/MA41123A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44Antibodies bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA041123A 2014-12-02 2015-12-01 Polythérapie pour le traitement du cancer MA41123A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086435P 2014-12-02 2014-12-02
US201562210545P 2015-08-27 2015-08-27

Publications (1)

Publication Number Publication Date
MA41123A true MA41123A (fr) 2017-10-10

Family

ID=56092663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041123A MA41123A (fr) 2014-12-02 2015-12-01 Polythérapie pour le traitement du cancer

Country Status (9)

Country Link
US (1) US20170266276A1 (fr)
EP (1) EP3226901A4 (fr)
JP (1) JP2018502833A (fr)
CN (1) CN107708731A (fr)
AU (1) AU2015358506A1 (fr)
CA (1) CA2969401A1 (fr)
MA (1) MA41123A (fr)
MX (1) MX2017006938A (fr)
WO (1) WO2016090024A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3009148B1 (fr) 2007-07-02 2018-08-22 Oncomed Pharmaceuticals, Inc. Compositions et procédés de traitement et de diagnostic d'un cancer
EP3401329A1 (fr) 2011-07-15 2018-11-14 OncoMed Pharmaceuticals, Inc. Agents de fixation aux protéines rspo et leurs utilisations
JP6335896B2 (ja) 2012-07-13 2018-05-30 オンコメッド ファーマシューティカルズ インコーポレイテッド Rspo3結合剤およびその使用法
ES2816624T3 (es) 2014-02-28 2021-04-05 Merus Nv Anticuerpos que se unen a EGFR y ERBB3
CA2961374A1 (fr) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Traitement de maladies fibrotiques
KR20250157457A (ko) 2015-10-23 2025-11-04 메뤼스 엔.페. 암 성장을 억제하는 결합 분자
AU2017326751B2 (en) * 2016-09-16 2024-10-10 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
WO2018182422A1 (fr) 2017-03-31 2018-10-04 Merus N.V. Anticorps bispécifiques de liaison à l'erbb-2 et erbb-3 destinés à être utilisés dans le traitement des cellules (f) qui présentent un gène de fusion (nrg1)
CN111148764B (zh) 2017-05-17 2025-08-12 美勒斯公司 用于乳腺癌的ErbB-2/ErbB-3双特异性抗体与内分泌治疗的组合
PL3665198T3 (pl) 2017-08-09 2025-06-09 Merus N.V. Przeciwciała wiążące egfr i cmet
JP7370997B2 (ja) * 2017-12-07 2023-10-30 ナショナル ヘルス リサーチ インスティテューツ 抗rspo3抗体
MX2022012683A (es) 2020-04-09 2023-01-11 Verve Therapeutics Inc Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10257252A1 (de) * 2002-12-07 2004-08-12 Deere & Company, Moline Presse, insbesondere Rundballenpresse
EP3009148B1 (fr) * 2007-07-02 2018-08-22 Oncomed Pharmaceuticals, Inc. Compositions et procédés de traitement et de diagnostic d'un cancer
EP3401329A1 (fr) * 2011-07-15 2018-11-14 OncoMed Pharmaceuticals, Inc. Agents de fixation aux protéines rspo et leurs utilisations
JP6335896B2 (ja) * 2012-07-13 2018-05-30 オンコメッド ファーマシューティカルズ インコーポレイテッド Rspo3結合剤およびその使用法
CN105142641A (zh) * 2013-03-12 2015-12-09 广州源生医药科技有限公司 用于治疗癌症的化合物

Also Published As

Publication number Publication date
EP3226901A2 (fr) 2017-10-11
CN107708731A (zh) 2018-02-16
WO2016090024A3 (fr) 2016-08-04
EP3226901A4 (fr) 2018-08-08
AU2015358506A1 (en) 2017-06-08
JP2018502833A (ja) 2018-02-01
WO2016090024A4 (fr) 2016-09-22
WO2016090024A2 (fr) 2016-06-09
US20170266276A1 (en) 2017-09-21
CA2969401A1 (fr) 2016-06-09
MX2017006938A (es) 2017-08-24

Similar Documents

Publication Publication Date Title
MA41555A (fr) Polythérapie pour le traitement du cancer
IL296080B1 (en) Method for treating cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
MA45429A (fr) Polythérapie pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3621592A4 (fr) Polythérapies pour le traitement du cancer
EP3322448A4 (fr) Nouvelle approche pour le traitement du cancer par immunomodulation
MA41858A (fr) Polythérapie fgfr/pd-1 destinée au traitement du cancer
MA41123A (fr) Polythérapie pour le traitement du cancer
LT3119808T (lt) Antikūnų kompozicijos vėžio gydymui
EP3377068A4 (fr) Polythérapie comprenant des analogues de la quinolone tétracyclique pour le traitement du cancer
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
MA41449A (fr) Polythérapies pour le traitement de cancers
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3362066A4 (fr) Polythérapie pour le traitement de tumeurs malignes
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3285773A4 (fr) Polythérapie pour le traitement du cancer
MA47408A (fr) Traitement du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3375108A4 (fr) Traitement dewlan
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
HUE040167T2 (hu) Rákkezelés
EP4067461C0 (fr) Procédé de réduction du point d'écoulement à efficacité élevée